KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Shares Outstanding (Weighted Average) (2016 - 2026)

Gsk has reported Shares Outstanding (Weighted Average) over the past 18 years, most recently at $1818692.7 billion for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 7.04% year-over-year to $1818692.7 billion; the TTM value through Mar 2026 reached $1818692.7 billion, up 7.04%, while the annual FY2025 figure was $1794394.2 billion, 103712487.53% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $1818692.7 billion at Gsk, up from $1794394.2 billion in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $4915520.5 billion in Q1 2023 and troughed at $1.7 billion in Q4 2024.
  • A 5-year average of $1617416.3 billion and a median of $1707491.1 billion in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 65.6% in 2024 and later soared 103712487.53% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $4.7 billion in 2022, then grew by 6.5% to $5.0 billion in 2023, then tumbled by 65.6% to $1.7 billion in 2024, then soared by 103712487.53% to $1794394.2 billion in 2025, then grew by 1.35% to $1818692.7 billion in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for GSK at $1818692.7 billion in Q1 2026, $1794394.2 billion in Q4 2025, and $1820289.5 billion in Q3 2025.